Daily non-political popular news in brief.

Improvement following ADHD treatment sustained in most children

Most children treated in a variety of ways for Attention Deficit Hyperactivity Disorder showed sustained improvement after three years, in a major follow-up study. Yet increased risk for behavioral problems, including delinquency and substance use, remained higher than normal. Initial advantages of medication management alone or in combination with behavioral treatment over purely behavioral or routine community care waned in the years after 14 months of controlled treatment ended.

Read more »

Keywords: improvement, following, adhd, treatment, sustained, children

« Previous | Next »

Similar news on "Improvement following ADHD treatment sustained in most children":

1. Lisdexamfetamine dimesylate in ADHD phase 3 data presented
   10-27-2006 · EurekAlert!
   Shire and New River Pharmaceuticals Inc. announce that their investigational ADHD treatment, lisdexamfetamine dimesylate, also known as NRP104 or LDX, yielded a 60 percent improvement in the primary rating scale scores for symptoms of Attention-Deficit/Hyperactivity Disorder in children aged 6 to 12 years who received six months of treatment in an open-label phase 3 study presented at a national meeting of child and adolescent psychiatrists.
   Similar news · Read more »
   
2. 12-month study demonstrated tolerability and efficacy of Daytrana
   05-23-2007 · EurekAlert!
   Shire plc announced that Daytrana, the first and only non-oral medication approved for treatment of ADHD in children aged 6 to 12 years, provided significant improvement in symptom control and tolerability, according to results of a 12-month open-label study presented at the American Psychiatric Association annual meeting.
   Similar news · Read more »
   
3. Long-term treatment with VYVANSE, first prodrug stimulant, demonstrates significant efficacy in ADHD
   05-23-2007 · EurekAlert!
   Shire plc today announced that VYVANSE effectively controlled ADHD symptoms in children aged 6 to 12 years. In addition, 95 percent of children taking VYVANSE daily for 12 months showed overall improvement, according to phase 3 open-label extension trial results. Further analysis of phase 2 clinical data demonstrated that VYVANSE provided consistent time to maximum concentration of d-amphetamine from patient to patient. Both studies were presented at the annual meeting of the American Psychiatric Association.
   Similar news · Read more »
   
4. HGS announces results of Phase 2B trial of Albuferon for chronic hepatitis C
   11-05-2007 · EurekAlert!
   This Phase 2b study demonstrated that, with half as many injections as Pegasys (peginterferon alfa 2a), Albuferon was just as effective in achieving sustained virologic response -- an undetectable amount of virus in the blood at 24 weeks following the end of treatment -- with comparable safety and less impairment of health-related quality of life on treatment. Albuferon is administered every two weeks, while peginterferon alfa-2a requires administration every week.
   Similar news · Read more »
   
5. Ustekinumab Phase 3 data show long-term improvement of chronic plaque psoriasis
   02-02-2008 · EurekAlert!
   One-year data from a second double-blind, placebo-controlled Phase 3 study showed therapy with ustekinumab given every 12 weeks provided sustained, clinically meaningful improvement in the treatment of moderate to severe psoriasis. According to findings presented at the Annual Meeting of the American Academy of Dermatology, 87 percent and 91 percent of patients responding to ustekinumab 45 mg or 95 mg maintenance therapy, respectively, sustained at least a 75 percent improvement in psoriasis through one year.
   Similar news · Read more »
   
6. Gene predicts better outcome as cortex normalizes in teens with ADHD
   08-06-2007 · EurekAlert!
   Brain areas that control attention were thinnest in children with attention deficit hyperactivity disorder who carried a particular version of a gene. However, the areas, on the right side of the brain's cortex, normalized during the teen years, coinciding with clinical improvement. While the gene variant increased risk for ADHD, it also predicted better clinical outcomes and higher IQ than two other common versions of the same gene in youth with ADHD.
   Similar news · Read more »
   
7. Nonmedicinal treatment touted for preschoolers with ADHD
   08-21-2007 · EurekAlert!
   Researchers from Lehigh University and Lehigh Valley Hospital report their findings in the current issue of School Psychology Review, which is devoted to ADHD. Teachers also noted increases in early literacy skills. Goal of the study was to ease problems associated with the lifelong disorder before children enroll in elementary school.
   Similar news · Read more »
   
8. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
   09-03-2007 · EurekAlert!
   An estimated 8.7 percent of U.S. children age 8 to 15 meet diagnostic criteria for attention-deficit/hyperactivity disorder, but fewer than half receive treatment, according to a report in the September issue of Archives of Pediatrics and Adolescent Medicine, one of the JAMA/Archives journals.
   Similar news · Read more »
   
9. Testosterone patch benefits women with low sexual desire
   08-14-2007 · EurekAlert!
   Novel research published in the current issue of The Journal of Sexual Medicine supports the claim that women with hypoactive sexual desire disorder or HSDD (persistent or recurrent deficiency and/or absence of sexual fanatasies/thoughts, and/or desire for, or receptivity to, sexual activity, which causes personal distress) show noted improvement in sexual desire and sexual function following low dose testosterone treatment.
   Similar news · Read more »
   
10. Mayo Clinic study indicates medication for ADHD may help student outcomes
    09-18-2007 · EurekAlert!
    In an 18-year-study on attention-deficit/hyperactivity disorder, Mayo Clinic researchers found that treatment with prescription stimulants is associated with improved long-term academic success of children with ADHD. The Mayo Clinic results are the first population-based data to show stimulant drug therapy helps improve long-term school outcomes.
    Similar news · Read more »